Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P52566
UPID:
GDIR2_HUMAN
Alternative names:
Ly-GDI; Rho-GDI beta
Alternative UPACC:
P52566; B5BU79
Background:
Rho GDP-dissociation inhibitor 2, also known as Rho-GDI beta or Ly-GDI, plays a crucial role in regulating the GDP/GTP exchange reaction of Rho proteins. By inhibiting the dissociation of GDP from them and the subsequent binding of GTP, it directly influences the reorganization of the actin cytoskeleton mediated by Rho family members.
Therapeutic significance:
Understanding the role of Rho GDP-dissociation inhibitor 2 could open doors to potential therapeutic strategies.